JeffreySMillerMD

Hematology • Minneapolis, MN

Professor, Medicine, University of Minnesota Medical School

Join to view full profile

Are you Dr. Miller?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 72 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
516 Delaware St SE
Suite 5100 Clinic 5B University of Minnesota Physicia
Minneapolis, MN 55455
Phone+1 612-273-2800

Summary

Dr. Jeffrey Miller, MD is a hematologist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota and Iowa. He is affiliated with M Health Fairview University of Minnesota Medical Center and is a Professor at University of Minnesota Medical School.

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1988 - 1991
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1985 - 1988
Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

MN State Medical License 1991 - 2025
IA State Medical License 1985 - 1988
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 1999

Clinical Trials

Vaccination With Tetanus and KLH to Assess Immune Responses. Start of enrollment: 2002 Jul 01
Terminated
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors Start of enrollment: 2003 Oct 01
Completed
Phase 1
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia Start of enrollment: 1995 Dec 01
Completed
Not Applicable
Post Transplant Donor Lymphocyte Infusion Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2005 Mar 01
Completed
Phase 2
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 2
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) Start of enrollment: 2011 Sep 01
Completed
Phase 1
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Start of enrollment: 2013 Feb 15
Completed
Phase 1
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Start of enrollment: 2013 Nov 11
Completed
Phase 1, Phase 2
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Oct 01
Unknown status
Phase 1
Join now to see all

Publications & Presentations

PubMed

20 citations
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Philippa R Kennedy, Martin Felices, Jeffrey S Miller
Stem Cell Research & Therapy. 2022-04-12
311 citations
Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein
Veronika Bachanova, Sarah Cooley, Todd E. DeFor, Michael R. Verneris, Bin Zhang
Blood. 2014-06-19
8 citations
A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Philippa R Kennedy, Daniel A Vallera, Brianna Ettestad, Caroline Hallstrom, Behiye Kodal
Frontiers in Immunology. 2023-01-01

Press Mentions

GT Biopharma Announces Sponsored Research Agreement with Dr. Jeffrey S. Miller of the University of MinnesotaAugust 8th, 2024